1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Zota Health Care Ltd.

Zota Health Care Ltd.

NNSE:ZOTA
1,273.10
INR
-36.10
(-2.76%)
-31.51EPS
49.07BMarket Cap
Nov 18Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
24.92
28.08
32.19
35.6
32.34
34.86
38.73
43.48
52.72
55.63
70.38
107.44
163.65
180.48
Basic EPS, GAAP
1.56
2.12
2.54
2.76
3.02
2.26
1.12
-0.09
3.58
-2.29
-5.59
-20.68
-22.46
-31.42
Free Cash Flow per Basic Share
0.94
1.77
1.58
0.71
-2.39
-2.59
-0.25
-1.68
4.05
-5.77
-8.85
-35.18
-59.96
- -
Dividend per Share
0.6
0.71
0.71
0.71
1.46
2.14
1
1
1.01
1.5
1.01
1.01
0.93
- -
Book Value per Share
6.36
7.37
9.43
10.99
28.41
28.06
28.02
26.99
35.62
31.94
34.81
78.12
200.24
- -
Tangible Book Value per Share
6.36
7.37
9.09
10.26
27.47
26.77
25.02
24.36
33.45
30.23
33.24
76.4
195.02
- -
Basic Weighted Avg Shares
20
20
20
20
24
25
25
25
25
25
26
27
33
32
Sales/Revenue/Turnover
501
565
647
716
779
856
951
1,068
1,312
1,400
1,805
2,930
5,387
5,833
Operating Margin (%)
10.7
12.35
12.94
12.56
12.8
7.67
2.61
-2.01
8.54
-2.73
-6.99
-16.41
-11.91
-15.61
Depreciation Expense
12
15
12
11
9
14
21
32
37
120
202
432
825
917
Net Income, GAAP
31
43
51
55
73
55
27
-2
89
-58
-143
-564
-739
-1,015
Effective Tax Rate (%)
33.37
32.59
33.85
33.73
35.92
29.37
29
- -
28.39
- -
- -
- -
- -
- -
Profit Margin (%)
6.25
7.55
7.89
7.74
9.34
6.48
2.88
-0.2
6.79
-4.12
-7.95
-19.25
-13.73
-17.41
Working Capital
100
121
173
207
344
426
403
430
409
437
379
835
2,199
- -
LT Debt
32
20
22
25
- -
- -
- -
- -
125
363
632
1,075
1,899
- -
Total Equity
156
181
232
270
698
689
688
663
896
804
900
2,272
6,962
- -
Return on Invested Capital (%)
18.79
21.88
22.86
21.1
12.64
6.46
2.56
- -
9.39
- -
- -
- -
- -
- -
Return on Capital (%)
18.8
21.81
22.8
21.18
14.55
8.02
3.99
- -
10.65
- -
- -
- -
- -
- -
Return on Common Equity (%)
21.23
25.28
24.76
22.1
15.02
8
3.98
-0.31
11.43
-6.79
-16.85
-35.96
-16.12
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
805
- -
LT Borrowings
- -
64
- -
LT Finance Leases
- -
1,836
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
35
35
Market Capitalization
52,171
36,877
49,067

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
4,572
- -
Cash, Cash Equivalents & STI
- -
956
- -
Accounts Receivable, Net
- -
735
- -
Inventories
- -
1,926
- -
Total Current Liabilities
- -
2,373
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
805
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
56.58%
79.15%
206.47%
Free Cash Flow
-17.5%
-20.72%
105.7%
Net Income, GAAP
-419.84%
-811.23%
31.1%
Sales/Revenue/Turnover
25.74%
40.93%
83.86%
Total Cash Common Dividend
- -
7.76%
11.81%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
563
673
721
973
2,930
2026
1,036
- -
1,430
1,632
5,387
2027
1,736
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-4.8
-4.57
-6.8
-4.57
-20.68
2026
-4.92
- -
-9.44
-4.13
-22.46
2027
-12.58
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.01
2026
- -
- -
- -
- -
0.93
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sujit Paul
Full Time Employees
635
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Zota House Surat GU India 394210
IPO Date
May 10, 2017
Website
zotahealthcare.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Zota Health Care Limited (ZOTA.NS) manufactures, markets, and distributes a broad portfolio of pharmaceutical and healthcare products in India. The company offers finished dosage formulations including tablets, capsules, syrups, ointments, injectables, and dry syrups across therapeutic categories such as anti-infectives, gastro-intestinal, pain management, vitamins and minerals, anti-diabetics, cardiac care, dermatology, and nutraceuticals; it also provides active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and contract manufacturing services for generics and branded formulations. Zota Health Care operates primarily in the Indian pharmaceutical sector, targeting retail pharmacies, hospitals, clinics, and institutional customers nationwide, with distribution through a network of carrying and forwarding agents and super stockists. Founded in 2000 and headquartered in Surat, Gujarat, the company maintains manufacturing facilities compliant with WHO-GMP standards and focuses on domestic markets while exploring export opportunities. In recent developments, Zota Health Care reported robust financial growth in fiscal year 2025, with revenue increasing over 20% year-over-year driven by expanded production capacity and new product launches in high-demand segments like anti-infectives and chronic therapies; it also strengthened its market position through strategic investments in R&D for specialty generics and enhanced supply chain efficiencies amid industry consolidation.